Articles From: TESSCO Technologies Schedules First-Quarter Fiscal 2015 Earnings Release and Conference Call to Tetraphase to Present Research at ICAAC on Its Novel Chemistry Platform’s Ability to Address Antibiotic Resistance


TESSCO Technologies Incorporated (Nasdaq:TESS), Your Total Source® for the product and value chain solutions to build, use and resell wireless systems, will report financial results for its first fiscal quarter ended June 29, 2014 after the market closes on Wednesday, July 23, 2014.
Sign-up for TESSCO Technologies Schedules First-Quarter Fiscal 2015 Earnings Release and Conference Call investment picks
Tessera Technologies, Inc. (NASDAQ: TSRA) ("Tessera" or the “Company") and Micron Technology, Inc. (“Micron”) (NASDAQ: MU) announced today the execution of new, multiyear technology and patent license agreements.
Sign-up for Tessera Technologies and Micron Technology Announce Execution of New Technology and Patent License Agreements investment picks
Tessera Technologies, Inc. (NASDAQ: TSRA) (the “Company” or “we”) today announced strong financial results for the second quarter of 2014.
Sign-up for Tessera Technologies Announces Strong Second Quarter 2014 Results investment picks
Tessera Technologies, Inc. (NASDAQ: TSRA) ("Tessera" or the “Company") will announce its financial results for the second quarter ended June 30, 2014 on Monday, August 4, 2014, following the close of the market.
Sign-up for Tessera Technologies to Report Second Quarter 2014 Results on Monday, August 4 investment picks
Tessera Technologies, Inc. (NASDAQ:TSRA) ("Tessera" or the "Company") today announced it will host an Analyst & Investor Day in New York City on Friday, September 5, 2014.
Sign-up for Tessera to Host Analyst & Investor Day in New York on September 5 investment picks
2014/09/15
Neither income-centric nor strictly total return, a hybrid distribution approach charts a steady course for our retirement bucket portfolio.
Sign-up for Testing a Blended Approach to Retirement Income investment picks
2014/7/17
GULFPORT, Miss.
Sign-up for Testing milestones reached at Kemper investment picks
2014/8/28
By Betsy McKay The National Institutes of Health said Thursday it will begin testing an experimental Ebola vaccine in humans next week, accelerating research as an epidemic caused by the deadly virus continues to ravage West Africa.
Sign-up for Testing on Experimental Ebola Vaccine to Begin in U.S. investment picks
CHENGDU, China , Aug.
Sign-up for Testing Runs Progress Updates for TPI's Qionglai Facility investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0955298001&sourceType=1 http://www.ccnmatthews.com/logos/20090524-tethylo2.JPG BOZOI, KAZAKHSTAN --
Sign-up for Tethys Petroleum Limited: Kazakhstan Gas Well Testing Programme Results investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) today announced the planned dates for its third quarter 2014 results and conference call.
Sign-up for Tetra Tech Announces Planned Dates for Third Quarter 2014 Results and Conference Call investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) today announced results for the third quarter ended June 29, 2014, the declaration of a quarterly dividend and changes to the share buyback program.
Sign-up for Tetra Tech Reports Third Quarter Results, Quarterly Dividend and Changes to Share Buyback investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded a five-year, $23 million single-award contract with the U.S. Environmental Protection Agency (EPA) to assess and reduce the human health and ecological risk from contaminated fish, sediments, and water-borne pathogens in fresh and marine waters.
Sign-up for Tetra Tech Wins $23 Million U.S. EPA Water Contract investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded a five-year, $23.6 million single-award contract with the U.S. Navy to assess and mitigate environmental impacts from expanded training grounds at the Marine Corps Air Ground Combat Center (MCAGCC) in Twentynine Palms, California.
Sign-up for Tetra Tech Wins $23.6 Million U.S. Navy Environmental Contract investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded a $64 million contract to provide technical assistance for the Power Africa Transactions and Reform Program funded by the U.S. Agency for International Development.
Sign-up for Tetra Tech Wins $64 Million USAID Power Africa Contract investment picks
THE WOODLANDS, Texas , July 20, 2014 /PRNewswire/ -- TETRA Technologies, Inc. (TETRA or the Company) (NYSE:TTI) today announced that its majority owned, publicly-traded partnership, Compressco Partners, L.P. (Compressco or the Partnership), has entered into a definitive agreement to purchase all the outstanding shares of Compressor Systems, Inc. (CSI) for $825 million in cash, subject to working capital and other adjustments.
Sign-up for Tetra Technologies, Inc. Announces Agreement By Compressco Partners, L.P. To Acquire Compressor Systems, Inc. investment picks
THE WOODLANDS, Texas , Aug.
Sign-up for TETRA Technologies, Inc. Announces Second Quarter 2014 Results And Revises 2014 Earnings Guidance investment picks
THE WOODLANDS, Texas , July 23, 2014 /PRNewswire/ -- TETRA Technologies, Inc. (TETRA or the Company) (NYSE:TTI) expects to release second quarter 2014 results on Friday, August 8, 2014 , and will host a conference call at 10:30 a.m. ET on that day to discuss the results.
Sign-up for TETRA Technologies, Inc. Announces Second Quarter 2014 Results Press Release And Conference Call Schedule investment picks
MALVERN, Pa., June 24, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) (the "Company" ) announced the closing of its previously-announced offering of $47 million aggregate principal amount of its 8% Convertible Senior Notes due 2019 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Notes will bear interest at a rate of 8.00% per annum, payable in cash semi-annually in arrears on June 15 and December 15 of each year, beginning on December 15, 2014.
Sign-up for TetraLogic Announces Closing of $47 Million Convertible Senior Notes Offering investment picks
MALVERN, Pa., June 17, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) (the "Company") announced the pricing of its offering of $47 million in aggregate principal amount of its 8% Convertible Senior Notes due 2019 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). When issued, the Notes will be the Company's unsecured and unsubordinated obligations and will rank senior in right of payment to all of the Company's indebtedness that is expressly subordinated in right of payment to the Notes; rank equal in right of payment to any of the Company's unsecured liabilities that are not so subordinated; be effectively subordinated to any of the Company's future secured indebtedness to the extent of the value of the assets securing such indebtedness; and rank structurally junior to all future indebtedness and liabilities of the Company's
Sign-up for TetraLogic Announces Pricing of $47 Million Offering of Convertible Notes investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that positive top-line results from the lead-in portion of its IGNITE 2 clinical trial, a two-part Phase 3 clinical trial studying the efficacy and safety of intravenous (IV) and oral formulations of eravacycline for the treatment of complicated urinary tract infections (cUTI), support advancement of the trial into its pivotal portion.
Sign-up for Tetraphase Pharmaceuticals Announces Positive Oral Dosing Data from Lead-in of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI Support Advancement to Pivotal Portion investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that it has completed patient enrollment in the lead-in portion of its IGNITE 2 clinical trial.
Sign-up for Tetraphase Pharmaceuticals Completes Enrollment in Lead-in Portion of IGNITE 2 Eravacycline Phase 3 Clinical Trial in cUTI investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that it has completed patient enrollment in IGNITE 1, its Phase 3 clinical trial evaluating the safety and efficacy of eravacycline in the treatment of complicated intra-abdominal infections (cIAI). The Company expects to report top-line results from IGNITE 1 in early first quarter 2015.
Sign-up for Tetraphase Pharmaceuticals Completes Enrollment of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-abdominal Infections investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results and key operational highlights for the second quarter ended June 30, 2014.
Sign-up for Tetraphase Pharmaceuticals Reports Second-Quarter 2014 Financial Results investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today announced its participation in two upcoming investor conferences: About Tetraphase Pharmaceuticals, Inc. Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic in the IGNITE program ( I nvestigating G
Sign-up for Tetraphase Pharmaceuticals to Participate in Upcoming Investor Conferences investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today announced its participation in the following upcoming conferences: About Tetraphase Pharmaceuticals, Inc. Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic in the IGNITE program ( I nvestigating G
Sign-up for Tetraphase Pharmaceuticals to Present at Upcoming Conferences investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer , will present at the annual Wedbush Life Sciences Conference on Wednesday, August 13 at 2:30 p.m. Eastern Time.
Sign-up for Tetraphase Pharmaceuticals to Present at Wedbush Life Sciences Conference investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that nine posters and one oral presentation on data related to the Company’s next-generation antibiotics portfolio – including its lead candidate eravacycline that is currently in Phase 3 clinical development for treatment of bacterial infections including multidrug-resistant (MDR) infections – will be presented at the upcoming 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The research will highlight: ICAAC 2014 occurs in Washington, DC from September 5 – 9, 2014, at the Walter E.
Sign-up for Tetraphase to Present Research at ICAAC on Its Novel Chemistry Platform’s Ability to Address Antibiotic Resistance investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: TESSCO Technologies Schedules First-Quarter Fiscal 2015 Earnings Release and Conference Call to Tetraphase to Present Research at ICAAC on Its Novel Chemistry Platform’s Ability to Address Antibiotic Resistance
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices